Industry
Biotechnology
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 09, 2024 | 8:22 pm
Portfolio Pulse from Benzinga Newsdesk
July 19, 2024 | 8:04 pm
Portfolio Pulse from Vandana Singh
June 24, 2024 | 4:06 pm
Portfolio Pulse from Benzinga Newsdesk
June 24, 2024 | 1:22 pm
Portfolio Pulse from Benzinga Newsdesk
June 24, 2024 | 1:02 pm
Portfolio Pulse from Benzinga Newsdesk
June 13, 2024 | 1:22 pm
Portfolio Pulse from Benzinga Insights
May 17, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
May 13, 2024 | 4:00 pm
Portfolio Pulse from Benzinga Newsdesk
May 10, 2024 | 8:55 pm
Portfolio Pulse from Benzinga Insights
April 22, 2024 | 12:07 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.